Lebenthal Global Advisors LLC Has $1.39 Million Position in Axon Enterprise, Inc. (NASDAQ:AXON)

Lebenthal Global Advisors LLC trimmed its holdings in Axon Enterprise, Inc. (NASDAQ:AXON) by 0.8% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,478 shares of the biotechnology company’s stock after selling 29 shares during the period. Lebenthal Global Advisors LLC’s holdings in Axon Enterprise were worth $1,390,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. PFG Investments LLC increased its stake in shares of Axon Enterprise by 0.6% in the 3rd quarter. PFG Investments LLC now owns 3,872 shares of the biotechnology company’s stock valued at $1,547,000 after purchasing an additional 25 shares during the last quarter. Mather Group LLC. lifted its stake in shares of Axon Enterprise by 3.7% in the third quarter. Mather Group LLC. now owns 759 shares of the biotechnology company’s stock valued at $303,000 after buying an additional 27 shares in the last quarter. CWM LLC lifted its position in shares of Axon Enterprise by 1.3% during the third quarter. CWM LLC now owns 2,856 shares of the biotechnology company’s stock valued at $1,141,000 after purchasing an additional 36 shares in the last quarter. SPC Financial Inc. lifted its position in shares of Axon Enterprise by 2.2% during the third quarter. SPC Financial Inc. now owns 1,773 shares of the biotechnology company’s stock valued at $708,000 after purchasing an additional 38 shares in the last quarter. Finally, Dorsey Wright & Associates lifted its position in shares of Axon Enterprise by 0.3% during the second quarter. Dorsey Wright & Associates now owns 14,053 shares of the biotechnology company’s stock valued at $4,135,000 after purchasing an additional 39 shares in the last quarter. Institutional investors own 79.08% of the company’s stock.

Insider Transactions at Axon Enterprise

In related news, CEO Patrick W. Smith sold 80,300 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $371.78, for a total value of $29,853,934.00. Following the completion of the sale, the chief executive officer now directly owns 3,015,366 shares of the company’s stock, valued at approximately $1,121,052,771.48. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Axon Enterprise news, Director Jeri Williams sold 110 shares of the stock in a transaction that occurred on Monday, September 30th. The shares were sold at an average price of $400.00, for a total transaction of $44,000.00. Following the completion of the sale, the director now directly owns 1,934 shares of the company’s stock, valued at $773,600. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Patrick W. Smith sold 80,300 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $371.78, for a total transaction of $29,853,934.00. Following the sale, the chief executive officer now directly owns 3,015,366 shares of the company’s stock, valued at approximately $1,121,052,771.48. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 371,172 shares of company stock worth $137,000,162 in the last quarter. Company insiders own 6.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on AXON. Barclays raised their price target on shares of Axon Enterprise from $381.00 to $387.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Bank of America assumed coverage on shares of Axon Enterprise in a research report on Wednesday, July 17th. They issued a “buy” rating and a $380.00 price objective on the stock. Northland Securities lifted their target price on shares of Axon Enterprise from $330.00 to $365.00 and gave the stock an “outperform” rating in a research note on Thursday, August 8th. Robert W. Baird lifted their target price on shares of Axon Enterprise from $360.00 to $400.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 10th. Finally, Craig Hallum boosted their price objective on shares of Axon Enterprise from $370.00 to $376.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $388.23.

Axon Enterprise Stock Up 0.9 %

AXON stock traded up $4.01 during trading on Friday, hitting $427.51. 58,508 shares of the stock traded hands, compared to its average volume of 517,208. Axon Enterprise, Inc. has a 1 year low of $209.02 and a 1 year high of $455.17. The firm’s 50 day moving average is $400.22 and its two-hundred day moving average is $339.14. The stock has a market cap of $32.31 billion, a price-to-earnings ratio of 111.74, a price-to-earnings-growth ratio of 11.18 and a beta of 0.94. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52.

Axon Enterprise (NASDAQ:AXON) last posted its earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.18. The business had revenue of $504.00 million for the quarter, compared to analysts’ expectations of $478.35 million. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The business’s revenue for the quarter was up 34.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.80 EPS. On average, sell-side analysts anticipate that Axon Enterprise, Inc. will post 1.79 EPS for the current year.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.